Cross Talk Between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2016 Apr 20

PMID 27090640

Citations 13

Authors

Ion Cristobal

Federico Rojo

Juan Madoz-Gurpide

Jesus Garcia-Foncillas

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.

Citing Articles

Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.

Akhoundova D, Fischer S, Triscott J, Lehner M, Thienger P, Maletti S Diagn Pathol. 2024; 19(1):83.

PMID: 38907236 PMC: 11191256. DOI: 10.1186/s13000-024-01511-3.

The yin and yang of chromosomal instability in prostate cancer.

Carceles-Cordon M, Orme J, Domingo-Domenech J, Rodriguez-Bravo V Nat Rev Urol. 2024; 21(6):357-372.

PMID: 38307951 PMC: 11156566. DOI: 10.1038/s41585-023-00845-9.

Prostate Cancer Stem Cells: Biology and Treatment Implications.

Koukourakis I, Platoni K, Kouloulias V, Arelaki S, Zygogianni A Int J Mol Sci. 2023; 24(19).

PMID: 37834336 PMC: 10573523. DOI: 10.3390/ijms241914890.

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.

Patterson J, Varkaris A, Croucher P, Ridinger M, Dalrymple S, Nouri M Cancer Res. 2022; 83(2):219-238.

PMID: 36413141 PMC: 9852064. DOI: 10.1158/0008-5472.CAN-22-1533.

Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.

Wang C, Chen Q, Xu H Discov Oncol. 2022; 12(1):40.

PMID: 35201496 PMC: 8777554. DOI: 10.1007/s12672-021-00433-6.

References

Nihal M, Stutz N, Schmit T, Ahmad N, Wood G . Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle. 2011; 10(8):1303-11. DOI: 10.4161/cc.10.8.15353. View

He Z, Zheng H, Lin H, Miao X, Zhong D . Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol. 2009; 15(33):4177-82. PMC: 2738815. DOI: 10.3748/wjg.15.4177. View

Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S . Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci. 2006; 97(4):271-6. PMC: 11159179. DOI: 10.1111/j.1349-7006.2006.00170.x. View

Zhang G, Zhang Z, Liu Z . Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol. 2013; 34(3):1887-94. DOI: 10.1007/s13277-013-0732-0. View

Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R . Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002; 29(6):354-8. DOI: 10.1034/j.1600-0560.2002.290605.x. View

Feng Y, Lin D, Shi Z, Wang X, Shen X, Zhang Y . Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer. 2008; 124(3):578-88. DOI: 10.1002/ijc.23990. View

Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P . Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 2005; 5(2-3):259-65. DOI: 10.1159/000085280. View

Cheng M, Wang B, Weng Z, Zhu X . Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem. 2011; 114(5):503-9. DOI: 10.1016/j.acthis.2011.09.004. View

Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K . Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59(12):2794-7. View

10.

Liu X, Li H, Song B, Liu X . Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010; 11(8):626-32. PMC: 2920445. DOI: 10.1038/embor.2010.90. View

11.

Feng Y, Yuan J, Maloid S, Fisher R, Copeland T, Longo D . Polo-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation. Biochem Biophys Res Commun. 2006; 349(1):144-52. DOI: 10.1016/j.bbrc.2006.08.028. View

12.

Li J, Karki A, Hodges K, Ahmad N, Zoubeidi A, Strebhardt K . Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer. Mol Cell Biol. 2015; 35(24):4185-98. PMC: 4648817. DOI: 10.1128/MCB.00825-15. View

13.

Mulholland D, Dedhar S, Wu H, Nelson C . PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006; 25(3):329-37. DOI: 10.1038/sj.onc.1209020. View

14.

Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S . Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol. 2005; 11(36):5644-50. PMC: 4481481. DOI: 10.3748/wjg.v11.i36.5644. View

15.

Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C . Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology. 2006; 70(3):231-7. DOI: 10.1159/000094416. View

16.

Feng B, Wang R, Chen L . MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2011; 317(2):184-91. DOI: 10.1016/j.canlet.2011.11.024. View

17.

Al Nakouzi N, Cotteret S, Commo F, Gaudin C, Rajpar S, Dessen P . Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget. 2014; 5(3):667-78. PMC: 3996665. DOI: 10.18632/oncotarget.1574. View

18.

Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S . Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther. 2009; 8(11):3024-35. PMC: 2783569. DOI: 10.1158/1535-7163.MCT-09-0365. View

19.

Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M . Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res. 2006; 66(11):5836-46. DOI: 10.1158/0008-5472.CAN-06-0343. View

20.

Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M . Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 2004; 90(4):815-21. PMC: 2410182. DOI: 10.1038/sj.bjc.6601610. View